By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Hegenheimermattweg 125

Allschwil    CH-4123  Switzerland
Phone: 41-61-567-1600 Fax: 41-61-567-1601



Drug Discovery

Company News
Polyphor Achieves Ahead Of Schedule First Milestone From Wellcome Trust For The Development Of Novel Antibiotics Against Gram-Negative Multidrug - Resistant Pathogens 7/18/2017 9:52:14 AM
Polyphor Contributes To The Progress In Understanding Neutrophil Elastase Science 7/10/2017 11:27:17 AM
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia 5/19/2017 10:56:06 AM
Polyphor Appoints Michael Altorfer As New CEO And Strengthens Executive Management Team 3/17/2015 10:12:40 AM
Polyphor Develops The Elastase Inhibitor POL6014 For Rare Lung Diseases Using PARI Pharma’s Eflow Technology Inhalation Device 1/9/2015 7:53:56 AM
Polyphor’s Lead Antibiotic POL7080 Receives Qualified Infectious Disease Product (QIDP) Designation From The FDA 11/12/2014 9:14:16 AM
Roche (RHHBY) to Pay Polyphor Up to $548 Million for Superbug Antibiotic 11/4/2013 7:13:44 AM
Polyphor Achieves First Milestone in Macrocycle Drug Discovery Collaboration With Boehringer Ingelheim Corporation 7/31/2013 9:15:00 AM
Polyphor Attracts Senior Pharma Professionals to Strengthen Its Board of Directors 6/11/2013 8:51:41 AM
Polyphor Reports Successful Phase I Results for Its Pseudomonas Selective Antibiotic POL7080 3/4/2013 11:46:40 AM